Page last updated: 2024-12-08
dihydrobunolol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dihydrobunolol: major metabolite of bunolol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 162349 |
| CHEBI ID | 29109 |
| MeSH ID | M0065344 |
Synonyms (13)
| Synonym |
|---|
| 38947-37-4 |
| (+-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol |
| dihydrobunolol |
| CHEBI:29109 |
| 5-[rac-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-ol |
| (+/-)-5-[(tert-butylaminol)-2'-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol |
| C04875 , |
| (+/-)-dihydrobunolol |
| (+/-)-5-[(tert-butylamino)-2'-hydroxypropoxy]-1,2,3,4-tetrahydro-1-naphthol |
| 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-ol |
| 1-naphthalenol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro- |
| 5-(3-(tert-butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalen-1-ol |
| DTXSID80959789 |
Research Excerpts
Overview
Dihydrobunolol (DHB) is an ocular metabolite equipotent to levobunolOL.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dihydrobunolol (DHB) is an equipotent metabolite of levobunolol." | ( Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. Acheampong, AA; Breau, A; Lam, S; Luo, W; Shackleton, M; Tang-Liu, DD, 1995) | 1.01 |
| "Dihydrobunolol is an ocular metabolite equipotent to levobunolol. " | ( Ocular metabolism of levobunolol. Richman, JB; Shackleton, M; Tang-Liu, DD, 1988) | 1.72 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The tpeak was 15 min after dosing and the Cmax was 4 micrograms/mL." | ( Disposition of levobunolol after an ophthalmic dose to rabbits. Liu, S; Neff, J; Sandri, R; Tang-Liu, DD, 1987) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| naphthols | Any hydroxynaphthalene derivative that has a single hydroxy substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.93) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||